ArticleAsian Pacific journal of cancer prevention : APJCP2025
Angiogenesis Pathway of the AMN3 Mouse Mammary Adenocarcinoma Cell Line.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAngiogenesis, the formation of new blood vessels, is a critical process that supports tumor growth, invasion, and metastasis. In breast cancer, tumor cells upregulate angiogenic factors to stimulate vascularization and ensure a continuous supply of oxygen and nutrients. The current AMN3 cell line, an important cancer cell model that is well established and used in cancer drug discovery, was used to investigate the role of specific angiogenic pathways in disease progression.
methodsWe conducted microarray protein expression analysis of the AMN3 mouse mammary adenocarcinoma cell line at 6 and 18 hours posttreatment.
resultsOur results revealed significant upregulation of several key angiogenic factors, including fibroblast growth factor (FGF), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and vascular endothelial growth factor-A (VEGF-A).
conclusionThese findings suggest that these factors contribute to creating a tumor microenvironment conducive to angiogenesis, thereby promoting tumor growth and dissemination. Targeting these factors may represent a promising therapeutic strategy for inhibiting tumor angiogenesis and controlling breast cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.